NEW YORK (GenomeWeb News) – French genome engineering company Cellectis said yesterday that that the European Patent Office has upheld one of its patents that has been the subject of ongoing litigation with US biotech firm Precision BioSciences.

However, in a statement released this morning, Precision BioSciences said that the EPO had "severely restricted" Cellectis' claims under the patent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: issues in reproducibility, circulating DNA predicts breast cancer relapse, and more.

Because of an autoimmune disorder, a man has been shedding live polioviruses for 28 years, according to an analysis appearing in PLOS Pathogens.

Being in a long-term collaboration can increase researchers' citation rates by 17 percent, a recent analysis says.

By analyzing tweets, Canadian researchers examine the public's view of gene patenting.